`
`___________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`___________________
`
`MYLAN PHARMACEUTICALS INC.
`Petitioner,
`
`v.
`
`MERCK SHARP & DOHME CORP.
`Patent Owner.
`
`U.S. Patent No. 7,326,708 to Cypes et al.
`Issue Date: February 5, 2008
`Title: Phosphoric Acid Salt of a Dipeptidyl Peptidase-IV Inhibitor
`
`Inter Partes Review No.: IPR2020-00040
`
`PETITIONER’S UPDATED MANDATORY NOTICE
`
`UNDER 37 C.F.R. 42
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`IPR2020-00040
`U.S. Patent No. 7,326,708
`
`Petitioner Mylan Pharmaceuticals, Inc. (“Mylan”) hereby updates its
`
`mandatory notices pursuant to 37 C.F.R. §42.8(a)(3) to reflect the addition of
`
`Lance A. Soderstrom as backup counsel for Mylan. Mr. Soderstrom’s USPTO
`
`Registration Number is 65,405 and thus, no pro hac vice will be filed. No other
`
`changes to Lead and Backup Counsel or service information are being made:
`
`Lead Counsel for Mylan:
`
`Jitendra Malik (Reg. No. 55,823; Tel. (704) 344-3185;
`
`jitty.malik@katten.com), attorney at Katten Muchin Rosenman LLP, 550 S.
`
`Tryon Street, Suite 2900, Charlotte NC 28202-4213.
`
`Backup Counsel for Mylan:
`
`Alissa Pacchioli (Reg. No. 74,252); Tel. (704) 344-3181;
`
`alissa.pacchioli@katten.com), attorney at Katten Muchin Rosenman LLP,
`
`550 S. Tryon Street, Suite 2900, Charlotte NC 28202-4213;
`
`Heike Radeke (Reg. No. 75,394); Tel. (704) 344-3180;
`
`heike.radeke@katten.com), Patent Agent at Katten Muchin Rosenman LLP,
`
`550 S. Tryon Street, Suite 2900, Charlotte NC 28202-4213;
`
`Christopher W. West (Reg. No. 74,724); Tel. (704) 344-3098;
`
`christopher.west@katten.com), attorney at Katten Muchin Rosenman LLP,
`
`550 S. Tryon Street, Suite 2900, Charlotte NC 28202-4213; and
`
`
`
`IPR2020-00040
`U.S. Patent No. 7,326,708
`
`Lance Soderstrom (Reg. No.65,405); Tel. (212) 940-6330;
`
`lance.soderstrom@katten.com), attorney at Katten Muchin Rosenman LLP,
`
`575 Madison Avenue, New York, NY 10022-2585.
`
`Service:
`
`Petitioners consent to e-mail service at the above e-mail addresses for lead
`
`and backup counsel.
`
`Dated: September 17, 2020
`
`Respectfully submitted,
`
`Katten Muchin Rosenman LLP
`
`/Jitendra Malik /
`Jitendra Malik (Reg. No. 55,823)
`
`for Petitioner Mylan
`Lead Counsel
`Pharmaceuticals, Inc.
`
`
`
`CERTIFICATION OF SERVICE ON PATENT OWNER
`
`Pursuant to 37 C.F.R. §§ 42.6(e), 42.8(b)(4), and 42.105, the undersigned
`
`certifies that on September 17, 2020, a complete copy of the Updated Mandatory
`
`Notice, was served via email to Patent Owner’s counsel at:
`
`sfisher@wc.com
`
`jberniker@wc.com
`
`smahaffy@wc.com
`
`asheh@wc.com
`
`bgenderson@wc.com
`
`ebaumgarten@wc.com
`
`azolan@wc.com
`
`kzullow@goodwinprocter.com
`
`sfischer@goodwinprocter.com
`
`jwong@winston.com
`
`ZCohen@winston.com
`
`CKlein@winston.com
`
`Cfundakowski@winston.com
`
`rfaegenburg@lernerdavid.com
`
`tvanbuskirk@lernerdavid.com
`
`mteschner@lernerdavid.com
`
`ERapalino@goodwinlaw.com
`
`
`
`Dated: September 17, 2020
`
`Respectfully submitted,
`
`Katten Muchin Rosenman LLP
`
`/Jitendra Malik /
`Jitendra Malik (Reg. No. 55,823)
`
`for Petitioner Mylan
`Lead Counsel
`Pharmaceuticals, Inc.
`
`